Engineered Substrate-Specific Delta PKC Antagonists to Enhance Cardiac Therapeutics.
暂无分享,去创建一个
[1] M. Disatnik,et al. Selective Phosphorylation Inhibitor of Delta Protein Kinase C-Pyruvate Dehydrogenase Kinase Protein-Protein Interactions: Application for Myocardial Injury in Vivo. , 2016, Journal of the American Chemical Society.
[2] M. Disatnik,et al. Mitochondrial reactive oxygen species at the heart of the matter: new therapeutic approaches for cardiovascular diseases. , 2015, Circulation research.
[3] S. Dowdy,et al. Cationic PTD/CPP-mediated macromolecular delivery: charging into the cell , 2015, Expert opinion on drug delivery.
[4] G. Iervasi,et al. Mitochondria as Key Targets of Cardioprotection in Cardiac Ischemic Disease: Role of Thyroid Hormone Triiodothyronine , 2015, International journal of molecular sciences.
[5] Z. Bosnjak,et al. Cdk1, PKCδ and calcineurin-mediated Drp1 pathway contributes to mitochondrial fission-induced cardiomyocyte death. , 2014, Biochemical and biophysical research communications.
[6] M. White,et al. Insulin Receptor Substrates Are Essential for the Bioenergetic and Hypertrophic Response of the Heart to Exercise Training , 2014, Molecular and Cellular Biology.
[7] M. Chiong,et al. Drp1 Loss-of-function Reduces Cardiomyocyte Oxygen Dependence Protecting the Heart From Ischemia-reperfusion Injury , 2014, Journal of cardiovascular pharmacology.
[8] Lei Yuan,et al. MARCKS regulates membrane targeting of Rab10 vesicles to promote axon development , 2014, Cell Research.
[9] S. Archer,et al. Dynamin‐related protein 1 (Drp1)‐mediated diastolic dysfunction in myocardial ischemia‐reperfusion injury: therapeutic benefits of Drp1 inhibition to reduce mitochondrial fission , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[10] K. Das,et al. Protein kinase C, an elusive therapeutic target? , 2012, Nature Reviews Drug Discovery.
[11] S. Steinberg. Cardiac actions of protein kinase C isoforms. , 2012, Physiology.
[12] Jeewon Kim,et al. PKCδ activation mediates angiogenesis via NADPH oxidase activity in PC‐3 prostate cancer cells , 2011, The Prostate.
[13] R. Sobel,et al. Aberrant mitochondrial fission in neurons induced by protein kinase Cδ under oxidative stress conditions in vivo , 2011, Molecular biology of the cell.
[14] D. Mochly‐Rosen,et al. Highly Specific Modulators of Protein Kinase C Localization: Applications to Heart Failure. , 2010, Drug discovery today. Disease mechanisms.
[15] P. Chakrabarti,et al. Conserved residue clusters at protein-protein interfaces and their use in binding site identification , 2010, BMC Bioinformatics.
[16] Sang-Bing Ong,et al. Inhibiting Mitochondrial Fission Protects the Heart Against Ischemia/Reperfusion Injury , 2010, Circulation.
[17] T. L. Archuleta,et al. Oxidant stress-induced loss of IRS-1 and IRS-2 proteins in rat skeletal muscle: role of p38 MAPK. , 2009, Free radical biology & medicine.
[18] C. Granger,et al. Intracoronary KAI-9803 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction , 2008, Circulation.
[19] R. Sobel,et al. Sustained pharmacological inhibition of deltaPKC protects against hypertensive encephalopathy through prevention of blood-brain barrier breakdown in rats. , 2007, The Journal of clinical investigation.
[20] S. Dowdy,et al. TAT transduction: the molecular mechanism and therapeutic prospects. , 2007, Trends in molecular medicine.
[21] D. Mochly‐Rosen,et al. Insight into intra- and inter-molecular interactions of PKC: design of specific modulators of kinase function. , 2007, Pharmacological research.
[22] M. Quon,et al. PKCδ-mediated IRS-1 Ser24 phosphorylation negatively regulates IRS-1 function , 2006 .
[23] K. Morgan,et al. MARCKS is a major PKC-dependent regulator of calmodulin targeting in smooth muscle , 2005, Journal of Cell Science.
[24] R. Begley,et al. Biodistribution of intracellularly acting peptides conjugated reversibly to Tat. , 2004, Biochemical and biophysical research communications.
[25] Daniel R. Caffrey,et al. Are protein–protein interfaces more conserved in sequence than the rest of the protein surface? , 2004, Protein science : a publication of the Protein Society.
[26] A. Newton,et al. Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. , 2003, The Biochemical journal.
[27] H. Matsuzaki,et al. Protein Kinase Cδ (PKCδ): Activation Mechanisms and Functions , 2002 .
[28] G. Cavallaro,et al. Molecular Dynamics Characterization of the C2 Domain of Protein Kinase Cβ* , 2002, The Journal of Biological Chemistry.
[29] G. Dorn,et al. Opposing cardioprotective actions and parallel hypertrophic effects of δPKC and ɛPKC , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[30] D. Mochly‐Rosen,et al. Binding Specificity for RACK1 Resides in the V5 Region of βII Protein Kinase C* , 2001, The Journal of Biological Chemistry.
[31] S. Schwarze,et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. , 1999, Science.
[32] D. Mochly‐Rosen,et al. A Protein Kinase C Translocation Inhibitor as an Isozyme-selective Antagonist of Cardiac Function* , 1996, The Journal of Biological Chemistry.
[33] F. Cohen,et al. An evolutionary trace method defines binding surfaces common to protein families. , 1996, Journal of molecular biology.
[34] A. Kraft,et al. A peptide encoding the c-Jun delta domain inhibits the activity of a c-jun amino-terminal protein kinase. , 1994, The Journal of biological chemistry.
[35] W. Miller,et al. A time-efficient, linear-space local similarity algorithm , 1991 .
[36] O. Langendorff,et al. Untersuchungen am überlebenden Säugethierherzen , 1895, Archiv für die gesamte Physiologie des Menschen und der Tiere.
[37] S. Corti,et al. Therapeutic applications of the cell-penetrating HIV-1 Tat peptide. , 2015, Drug discovery today.
[38] D. Maclean,et al. Therapeutic applications of cell-penetrating peptides. , 2011, Methods in molecular biology.